AFT Pharmaceuticals Limited

AFT

NZAFTE0001S4

Pharmaceuticals

End-of-day quote New Zealand S.E. Other stock markets 23:00:00 14/07/2024 BST			5-day change	1st Jan Change
3.03 ^NZD	-0.66%		+4.48%	-13.43%

07-09	New Zealand Shares Jump on US Rate Cut Optimism; AFT Pharmaceuticals to Launch Topical Medication in China	MT
07-09	AFT Pharmaceuticals to Launch Skin Infection Cream in China	MT

AFT Pharmaceuticals Limited Announces Retirement of Anita Baldauf as Independent Director

June 30, 2024 at 10:30 pm

AFT Pharmaceuticals independent director Anita Baldauf has announced her intention not to seek re-election and to retire as a director of the company at the upcoming shareholders meeting on August 2, 2024.

Latest news about AFT Pharmaceuticals Limited

New Zealand Shares Jump on US Rate Cut Optimism; AFT Pharmaceuticals to Launch Topical Medication in China	07-09	MT
AFT Pharmaceuticals to Launch Skin Infection Cream in China	07-08	MT
AFT Pharmaceuticals Announces an Agreement with Hainan Haiyao Co. Ltd to Distribute Crystaderm® Cream in China	07-08	CI
AFT Pharmaceuticals Limited Announces Retirement of Anita Baldauf as Independent Director	06-30	CI
New Zealand Shares Flat; Scott Technology Adds Meat Cutter to Brand Portfolio	06-04	MT
AFT Pharmaceuticals Partners with Alexso to Bring Pain Relief Drug to US Market	06-03	MT
AFT Pharmaceuticals Limited to Launch Maxigesic Rapid in the United States	06-03	CI
AFT Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-23	CI
Transcript : AFT Pharmaceuticals Limited, 2024 Earnings Call, May 23, 2024	05-22
AFT Pharmaceuticals' Net Profit Climbs 46% in Fiscal 2024; Dividend Declared	05-22	MT
AFT Pharmaceuticals Limited Announces Ordinary Dividend for the Twelve Months Ended Mach 31, 2024, Payable on July 4, 2024	05-22	CI
AFT Pharmaceuticals Signs Brazil Licensing Agreement for Maxigesic IV	05-01	MT
AFT Pharmaceuticals Limited Licenses Maxigesic IV in Brazil	04-30	CI
New Zealand Shares Rise on US Earnings Rally; AFT Pharmaceuticals to Develop Topical Scar Treatment	04-24	MT
AFT Pharmaceuticals, Massey Ventures, Gillies McIndoe Research Institute Partner to Develop Topical Scar Treatment	04-24	MT
AFT Pharmaceuticals Limited, Massey Ventures, Gilles Mcindoe Research Institute to Develop Scar Treatment	04-23	CI
New Zealand Shares Close Flat on Monday; Fletcher Building Chair Steps Down	03-04	MT
AFT Pharmaceuticals to Expand Global Footprint with Signing of Supply, Production Deals	03-04	MT
Aft Expands Its Co-Operation with Hikma Pharmaceuticals	03-03	CI
New Zealand Shares Rebound on Friday Close; AFT Pharmaceuticals Raises Operation Profit Guidance	02-16	MT
AFT Pharmaceuticals Boosts Operating Profit Guidance for Fiscal Year 2024	02-16	MT
AFT Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024	02-15	CI
AFT Pharmaceuticals' Licensee Launches Pain Relief Medication in US; Shares Rise 4%	02-07	MT
AFT Pharmaceuticals’ Maxigesic IV Launches in the US	02-06	MT
AFT Pharmaceuticals Ties Up with Belgian Firm to Develop Skin Medication	01-18	MT

Chart AFT Pharmaceuticals Limited

Duration

Period

More charts

Company Profile

AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.

Sector

Pharmaceuticals

Calendar

01/08/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for AFT Pharmaceuticals Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.03 NZD

Average target price

3.75 NZD

Spread / Average Target

+23.76%

Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
AFT PHARMACEUTICALS LIMITED	-13.43%	194M
ELI LILLY AND COMPANY	+63.05%	856B
NOVO NORDISK A/S	+38.95%	631B
JOHNSON & JOHNSON	-4.78%	359B
MERCK & CO., INC.	+17.52%	325B
ABBVIE INC.	+8.43%	297B
ASTRAZENECA PLC	+13.60%	244B
ROCHE HOLDING AG	+5.03%	234B
NOVARTIS AG	+16.27%	226B
AMGEN INC.	+14.63%	177B

Other Pharmaceuticals